⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARVN News
Arvinas, Inc
Form 8-K
sec.gov
ARVN
PFE
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
globenewswire.com
ARVN
PFE
Arevon Earns Gold Certification for Diversity, Equity, Inclusion, and Justice Initiatives from the Solar Energy Industries Association
prnewswire.com
ARVN
Form 8-K
sec.gov
ARVN
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
globenewswire.com
ARVN
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
globenewswire.com
ARVN
Form 8-K
sec.gov
ARVN
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
ARVN
Arvinas to Participate in Upcoming Investor Conferences
globenewswire.com
ARVN
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
globenewswire.com
ARVN